Keywords
Leuprolide acetate,Leuprolide,Lupron,acetate,structural formula,prostate cancer,uterine leiomyomata,endometriosis,central precocious pubertyleuprolide acetate,leuprolide acetate,eligard,gnrh agonist,gonadotropin-releasing hormone agonist,prostate cancer treatment,endometriosis treatment,hormone therapy,c59h84n16o12,chemical structure,structural formula,carboxylic acid,amide bond,peptide bond,aromatic ring,gnrh receptor,hormone regulation,testosterone suppression,ovarian suppression,pituitary downregulation,carbon,hydrogen,nitrogen,oxygen,single bonds,double bonds,aromatic bonds,antineoplastic agent,prostate cancer therapy,endocrine therapy,gonadotropin inhibition,pharmaceutical chemistry,drug design,therapeutics,pharmacodynamics,pharmacokinetics,long-acting injection,depot formulation,hormonal modulation,drug metabolism,clinical oncology,fertility treatment,leuprolide pharmacology,drug therapy,proj-creative-abx-24q2,proj-creative-abx-24q2-[novartis],Leuprolide acetate